JP-1366 not checked
Onconic Therapeutics Inc. · Zastaprazan 20mg
FollowEvery change as it happens, and a Monday email
Trials
5 active
13 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks”In the company’s words, NCT06439563 on ClinicalTrials.gov
- Tested for
- Non-erosive Gastroesophageal Reflux Disease, Peptic Ulcer, H. Pylori Eradication Therapy, Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD), Drug Drug Interaction (DDI)
- Main trialPhase 3
- “This study aims to evaluate the efficacy and safety of JP-1366 in Patients with NERD”In the company’s words, NCT07160790 on ClinicalTrials.gov
- Other names
- Zastaprazan 20mg
Other drugs for Peptic Ulcer
- IlaprazoleIl-Yang Pharm. Co., Ltd. · Phase 3
- FexuprazanDaewoong Pharmaceutical Co. LTD. · Phase 3
- AnaprazoleXuanzhu Biopharmaceutical Co., Ltd. · Phase 3
- JP-1366Livzon Pharmaceutical Group Inc. · Phase 3
- AD-115AAddpharma Inc. · Phase 1
Coming up3
- Aug 2027Phase 3 trial completes · ClinicalTrials.gov
- 6 Sep 2028Phase 3 trial completes · ClinicalTrials.gov
- 30 Oct 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 30 Jun 2026 | Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease | |
| Phase 3Recruiting | Aug 2027 | Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers | |
| Phase 3Not yet recruiting | 6 Sep 2028 | Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects | |
| Phase 3Not yet recruiting | 30 Oct 2028 | Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis | |
| Phase 1Recruiting | 30 Mar 2026 | to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban | |
| Phase 3Completed | 5 Jan 2023 | JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis | |
| Phase 3Completed | 10 Jul 2024 | Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer | |
| Phase 2Completed | 20 Oct 2020 | Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease | |
| Phase 1Completed | 16 Jan 2021 | Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers | |
| Phase 1Completed | 15 Mar 2021 | Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian | |
| Phase 1Completed | 9 Oct 2022 | Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers | |
| Phase 1Completed | 4 May 2023 | Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers | |
| Phase 1Completed | 20 Feb 2025 | Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026